Health and Healthcare
What Will Become of Valeant Pharmaceuticals?
Published:
Last Updated:
Valeant Pharmaceuticals International Inc. (NYSE: VRX) released its most recent quarterly report before the markets opened on Tuesday. At the same time, the firm announced that it would also be changing its name sometime in the very near future.
In July 2018, Valeant will become Bausch Health Companies and it will trade under a new ticker BHC on the New York Stock Exchange. The firm will maintain its present symbol for trading on the Toronto Stock Exchange.
As for the earnings, the firm said that it had $0.89 in earnings per share (EPS) on $2.0 billion in revenue. That compares with consensus estimates from Thomson Reuters of $0.60 in EPS on revenue of $1.95 billion. In the first quarter of last year, Valeant said it had EPS of $0.78 and $2.11 billion in revenue.
Valeant listed some quarterly highlights:
- Reported revenue in the Bausch + Lomb/International segment decreased by 3% compared to the first quarter of 2017 primarily due to divestitures and discontinuations; revenue in this segment grew organically by 2% compared to the first quarter of 2017
- Reported revenue in the Branded Rx segment decreased by 6% compared to the first quarter of 2017 primarily due to divestitures and discontinuations, and declines in the Ortho Dermatologics business; revenue in this segment grew organically by 8% compared to the first quarter of 2017
In terms of the outlook for the 2018 full year, the company expects to see revenues between $8.15 billion and $8.35 billion, with EBITDA in the range of $3.15 billion to $3.30 billion. The consensus estimates call for $3.13 in EPS on $8.23 billion in revenue for the year.
Joseph C. Papa, board chair and chief executive of Valeant, commented:
Our first-quarter 2018 results demonstrate that we are making significant progress in our turnaround. For the first time since 2015, the Company delivered overall organic revenue growth that tracked above expectations and was driven by our Branded Rx and Bausch + Lomb/International segments. As a result, we are raising our full-year revenue and Adjusted EBITDA (non-GAAP) guidance ranges to reflect our strong performance in the first quarter.
Valeant delivered $438 million in operating cash, putting cash and cash equivalents at $909 million at the end of the quarter, an increase from $720 million at the end of the previous fiscal year.
Shares of Valeant closed Monday at $18.16, with a consensus analyst price target of $17.14 and a 52-week range of $9.71 to $24.43. Following the announcement, the stock was up over 7% at $19.50 in early trading indications Tuesday.
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
